pharma · Ovarian Neoplasms · Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer
TESARO Bio Netherlands
TESARO Bio Netherlands B.V.
TESARO Bio Netherlands is a pharma organization headquartered in EU. Primary therapeutic focus areas include Ovarian Neoplasms, Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer, Recurrent or primary advanced (Stage II
EU HQ
EMA registrant Type
Company details
- Status
- Public
- HQ
- EU
- Programs
- 6
- Drugs
- 23
- Patents
- 0
4010-01-001
Phase 1 · other · Patients with Advanced Solid Tumors
4010-01-001 for Patients with Advanced Solid Tumors is a Phase 1 program (other) at TESARO Bio Netherlands B.V. with 1 ClinicalTrials.gov record(s).
Internal code 4010-01-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- TESARO Bio Netherlands B.V.
- Phase
- Phase 1
- Modality
- other
- Indication
- Patients with Advanced Solid Tumors
- Status
- active
- Trials
- 1